News and Announcements
OncoSil Medical Appoints Charles Rowland as President
- Published December 15, 2015 1:46PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
15th December 2015, ASX Announcement
OncoSil Medical Limited (ASX: OSL) (OncoSil Medical, the Company) is pleased to announce the appointment of Mr. Charles Rowland as President, OncoSil Medical USA.
Mr. Rowland was previously President of Sirtex Medical US from 2002 to 2006, and is a highly experienced healthcare executive with a successful record of commercialising medical devices and growing medical device companies in the diagnostics, cardiac patient management and liver cancer markets.
In his role with OncoSil Medical Mr. Rowland will be responsible for developing and executing the Company’s US Business plan and will be the Company’s official representative with the US FDA as it works towards US licensure for its lead product candidate, the OncoSilTM localiased radiation treatment for cancer.
To read the full announcement, please click here.
Company Updates
Forging a $100M Future: Why Prime Financial Puts People First in its Acquisition Strategy
ASX-listed Prime Financial Group is on an ambitious path to a $100 million revenue target. Chairman Simon Madder reveals their playbook isn’t just about capital; it’s about a founder-focused acquisition strategy where cultural fit is the ultimate litmus test. Discover how their unique partnership model, which includes offering significant equity to incoming founders, is fuelling one of the sector’s most compelling growth stories.
Wholesale Investor and MTPConnect Announce Strategic Partnership to Accelerate Investment in Australia’s Life Sciences Sector
Wholesale Investor and MTPConnect announce a landmark strategic partnership to bridge the funding gap in Australia’s life sciences sector. The collaboration creates a comprehensive capital engagement program, culminating in the Life Sciences Investor Day at the Emergence 2026 Conference
How Capital HQ Slashes Capital Raising Time by 80% for Founders
For startup founders, the capital raise process can feel like a relentless, time-consuming marathon, often diverting precious energy from the core business. “I remember finishing a capital raise at one stage and I remember spending about three months on it and for the money was brought in I thought that money could have been generated […]
Backed By Leading Investment Groups and Family Offices
